4 completed. 2 Not applicable, 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 2 | Completed 2 |
| Phase 1 | 1 | Completed 1 |
| Phase 2 | 1 | Completed 1 |
Follow BKR-017: new trials by email Literature Review of BKR-017 trials Research Report on BKR-017
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pharmacokinetics of Butyrate Tablet BKR-017 BKR-017 - Hypercholesterolemia | Completed | BioKier Inc. | 9 | 2025-07-16 | 2026-06-09 | |
| Butyrate Adjuvant Therapy for Type 1 Diabetes BKR-017 - Type1diabetes | Phase 1 / Phase 2 | Completed | Mayo Clinic | 6 | 2022-07-28 | 2026-03-31 |
| Dose-Response Study to Evaluate the Effect of BKR-017 on Insulin Resistance and Other Metabolic Parameters in Type 2 Diabetes Patients BKR-017 - Type 2 Diabetes | Not applicable | Completed | BioKier Inc. | 60 | 2021-04-18 | 2023-02-08 |
| Effects of BKR-017 on Insulin Resistance in Type 2 Diabetes Patients BKR-017 - Type 2 Diabetes | Not applicable | Completed | BioKier Inc. | 14 | 2020-06-16 | 2020-12-04 |
Diabetes Mellitus, Type 2 (2) · Hypercholesterolemia (1)
BioKier Inc. (3) · Mayo Clinic (1)
United States (4)
Adrian Vella, MD (1) · Frank Greenway, MD (1) · George Szewczyk, PhD (1)
R43HL174321 (1)